Shares of Amgen (AMGN) are sliding after the biotech company posted disappointing results from two drug studies.

Market Domination Hosts Julie Hyman and Josh Lipton break down the updates from Amgen's immunology and rare disease development pipeline and discuss how the drugmaker is stacking up to its competitors.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written by Melanie Riehl